AUA 2025 special: Dr. Neal Shore discusses phase 3 CREST study results

from EAU Podcasts · host European Association of Urology

At the 2025 American Urological Association (AUA 2025) Meeting in Las Vegas, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talked to Dr. Neal Shore (US) about the CREST study results: Sasanlimab in combination with bacillus calmette-guérin (BCG) improves event-free survival (EFS) versus bacillus calmette-guérin as standard of care in high-risk non- muscle-invasive bladder cancer (NMIBC). Dr. Shore explains the study rational, the results of the study, and the take home messages he presented during the meeting.

Episode metadata supplied by the publisher feed · Published May 3, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

AUA 2025 special: Dr. Neal Shore discusses phase 3 CREST study results

0:00 12:11

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EAU Podcasts?

This episode is 12 minutes long.

When was this EAU Podcasts episode published?

This episode was published on May 3, 2025.

Can I download this EAU Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!